Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Cogent Biosciences, Inc. (COGT) had Income from Continuous Operations of $-80.93M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-80.93M |
|
-- |
|
-- |
|
$83.36M |
|
$-83.36M |
|
$2.42M |
|
$-80.93M |
|
$-80.93M |
|
$-80.93M |
|
|
Income from Continuous Operations |
$-80.93M |
$-80.93M |
|
$-80.93M |
|
$-83.36M |
|
$-82.58M |
|
137.55M |
|
137.55M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$397.24M |
|
$5.27M |
|
$28.69M |
|
$425.93M |
|
$62.25M |
|
$44.25M |
|
$61.22M |
|
$123.47M |
|
$194.55M |
|
$302.46M |
|
$302.46M |
|
139.83M |
|
| Cash Flow Statement Financials | |
$-185.34M |
|
$-76.76M |
|
$289.56M |
|
$98.17M |
|
$125.63M |
|
$27.47M |
|
$30.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.38 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-186.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-41.60% |
|
-26.76% |
|
-19.00% |
|
-23.34% |
|
$2.16 |
|
$-1.35 |
|
$-1.35 |
|